SC1-PM-11-2016-2017
SC1-PM-11-2016-2017
10 projects · €57,585,216 total EU contribution (project-level) · 111 participating organizations · 20 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€57,585,216
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (16)
- Spain (15)
- France (13)
- UK (11)
- Italy (10)
- Netherlands (7)
- AT (6)
- HR (6)
- NO (4)
- PL (4)
- BE (3)
- CH (3)
- DK (3)
- FI (2)
- IE (2)
- IL (2)
- CZ (1)
- SI (1)
- TR (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM3 projects · FR
- ALTA SRLU2 projects · IT
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2 projects · FR
- CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES2 projects · FR
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN2 projects · DE
- UT2 projects · DE
- ECRIN2 projects · FR
- EFS2 projects · FR
- UDUS2 projects · DE
- ICON CLINICAL RESEARCH (U.K.) LIMITED2 projects · UK
- ICON Clinical Research GmbH2 projects · DE
- ICR2 projects · IE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain OSTEOproSPINE · 779340 | H2020 | €6,004,153 | €0 | Details |
Soraprazan - a new regenerative therapy for Stargardt's disease Soraprazan · 779317 | H2020 | €5,792,425 | €1,561,250 | Details |
Multisystem Cell Therapy for Improvement of Urinary Continence MUSIC · 731377 | H2020 | €2,349,521 | €187,500 | Details |
REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy RESPINE · 732163 | H2020 | €5,555,836 | €307,853 | Details |
A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies PACE · 733006 | H2020 | €7,206,219 | €65,019 | Details |
NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION RESTORE · 779316 | H2020 | €5,357,033 | €625,000 | Details |
Personalised maxillofacial bone regeneration MAXIBONE · 779322 | H2020 | €5,949,665 | €940,205 | Details |
ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs ORTHOUNION · 733288 | H2020 | €5,999,151 | €293,680 | Details |
Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial HIPGEN · 779293 | H2020 | €7,437,128 | €106,250 | Details |
Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina A phase II randomized, double-blinded, placebo-controlled study ReGenHeart · 731532 | H2020 | €5,934,086 | €1,478,193 | Details |